Rudy Mazzocchi Prepares to Release the Second Thriller in The EQUITY…

Within one year of the release of his award-winning Thriller, EQUITY of EVIL, Mazzocchi announces the pending release of the second novel in this trilogy based on the existence of revolutionary…(PRWeb January 01, 2013)Read the full story at http:/…


Click here for reuse options!
Copyright 2013 Biotechblog

A snapshot of the successful bio-clusters around the world: Lessons for South African biotechnology

Development of clusters has been one of the critical factors in the success of many countries in the field of biotechnology. Most of the literature has been focused on the biotechnology clusters in developed countries and much less attention has been p…


Click here for reuse options!
Copyright 2013 Biotechblog

Improving IPO market still not an exit path

Recent suggestions that improving IPO activity will lead biotech venture investors to lucrative exits seems to be a bit premature and detached from the reality of these deals. The maxim oft repeated by venture investors has never been truer: IPOs are f…


Click here for reuse options!
Copyright 2013 Biotechblog

China’s heparin revisited: What went wrong and has anything changed?

China is the world’s largest producer of crude heparin. In 2007, tainted Chinese crude heparin made its way into the global finished heparin supply chain killing 149 persons in 11 different countries including 81 deaths in the US. While China never f…


Click here for reuse options!
Copyright 2013 Biotechblog

The other side of innovation

Government sponsored comparative effectiveness research is the first step towards allowing Uncle Sam to push a restrictive formulary on more and more Americans – with step one in the process being unfettered (and unregulated) communications efforts. …


Click here for reuse options!
Copyright 2013 Biotechblog

Biotechnology valuation and governance: Drug development and board of directors composition

This paper examines the valuation of biotechnology firms and measure firm value relative to the firms’ drug development pipelines, alliances with other firms, and the varied composition of those firms’ boards of directors.  Unsurprisingly, the adv…


Click here for reuse options!
Copyright 2013 Biotechblog

Use of medicines for carved out indications – Time for a change in approach?

All stake-holders in the pharmaceutical industry recognise that valuable new medicines can be obtained from investing in the research and development of new uses for existing drugs.  The present system of awarding second medical use patents to origina…


Click here for reuse options!
Copyright 2013 Biotechblog

Fixing a broken drug development process

It costs about $1.2 billion to bring a single new drug to market in the U.S. today.[1] With a combination of high late-stage failure rates and the high cost of drug trials, the number of new drugs being approved by the FDA has flat-lined at historicall…


Click here for reuse options!
Copyright 2013 Biotechblog

%d bloggers like this: